Lead Plaintiff Deadline is March 18, 2019

NEW YORK, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of investors that acquired DBV Technologies S.A. (“DBV Technologies” or the “Company”) (NASDAQ: DBVT) American Depositary Receipts (“ADR’s”) between October 22, 2018 and December 19, 2018, inclusive (the “Class Period”).

Shareholders who purchased ADR’s of DBV Technologies S.A are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If you have incurred losses in the ADR’s of DBV Technologies S.A., you may, no later than March 18, 2019, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in DBV Technologies S.A.

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

The filed Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:

• DBV Technologies’ BLA for Viaskin Peanut failed to provide the FDA with sufficient data on manufacturing procedures and quality controls;
   
• consequently, DBV Technologies would have to withdraw their BLA for Viaskin Peanut; and
   
• as a result, defendants’ statements about DBV Technologies’ business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

On December 19, 2018, DBV Technologies revealed that, following discussions with the U.S. Food and Drug Administration (”FDA”), its Biologics License Application (“BLA”) for Viaskin Peanut was voluntarily withdrawn.

According to the Company, the FDA communicated that “the level of detail with regards to data on manufacturing and quality controls was insufficient in the BLA.” On this news, DBV Technologies’ share price fell $8.39, or nearly 60%, to close at $5.76 on December 20, 2018.

Wolf Haldenstein Adler Freeman & Herz LLP  has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.
Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.